Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects

Cancer Immunology, Immunotherapy

Volumn 61, Issue 10, 2012, Pages 1683-1697

  Rakhmilevich, Alexander L ^a,b   Baldeshwiler, Mark J ^a   Van De Voort, Tyler J ^a   Felder, Mildred A R ^c   Yang, Richard K ^a   Kalogriopoulos, Nicholas A ^a   Koslov, David S ^a   Van Rooijen, Nico ^d   Sondel, Paul M ^b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti CD40; CpG; Immunotherapy; Myeloid cells

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CD11B ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CELL PROTEIN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; NITRIC OXIDE; PROTEIN GR 1; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER CELL; CANCER INHIBITION; CELL ACTIVATION; CELL FUNCTION; CELL SELECTION; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA B16; MOUSE; NONHUMAN; PERITONEAL CAVITY; PERITONEUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD40; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CPG ISLANDS; FEMALE; IMMUNOTHERAPY; INTERFERON-GAMMA; LIPOPOLYSACCHARIDES; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELOID CELLS; NITRIC OXIDE; PERITONEAL NEOPLASMS;

EID: 84867572838     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1236-2     Document Type: Article

References (55)

1. De Souza AP, Bonorino C (2009) Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev Anticancer Ther 9:1317-1332
2. (Review) 2. Ostrand-Rosenberg S, Sinha P, Danna EA, Miller S, Davis C, Dissanayake SK (2004) Antagonists of tumor-specific immunity: tumor-induced immune suppression and host genes that co-opt the anti-tumor immune response. Breast Dis 20:127-135
3. Mantovani A, Allavena P, Sica A (2004) Tumour-Associated macrophages as a prototypic type II polarized phagocyte population: role in tumour progression. Eur J Cancer 40:1660-1667
4. Mullins DW, Martins RS, Elgert KD (2003) Tumor-derived cytokines dysregulate macrophage interferon-gamma responsiveness and interferon regulatory factor-8 expression. Exp Biol Med (Maywood) 228:270-277
5. Jaffe ML, Arai H, Nabel GJ (1996) Mechanisms of tumorinduced immunosuppression: evidence for contact-dependent T cell suppression by monocytes. Mol Med 2:692-701
6. Taams LS, van Amelsfort JM, Tiemessen MM, Jacobs KM, de Jong EC, Akbar AN, Bijlsma JW, Lafeber FP (2005) Modulation of monocyte/macrophage function by human CD4?CD25? regulatory T cells. Hum Immunol 66:222-230
7. Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S (2004) Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 64:2205-2211
8. Sinha P, Clements VK, Ostrand-Rosenberg S (2005) Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174:636-645
9. Talmadge JE (2007) Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 13:5243-5248
10. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162-174 (Review)
11. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22:238-244 (Review)
12. Apolloni E, Bronte V, Mazzoni A, Serafini P, Cabrelle A, Segal DM, Young HA, Zanovello P (2000) Immortalized myeloid suppressor cells trigger apoptosis in antigen-Activated T lymphocytes. J Immunol 165:6723-6730
13. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH (2006) Gr-1?CD115? immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123-1131
14. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S (2007) Prostaglandin E2 promotes tumor progression by inducing myeloid- derived suppressor cells. Cancer Res 67:4507-4513
15. Popovic PJ, Zeh HJ III, Ochoa JB (2007) Arginine and immunity. J Nutr 137:1681S-1686S (Review)
16. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S (2007) Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179:977-983
17. Leek RD, Harris AL (2002) Tumor-Associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 7:177-189
18. Knowles H, Leek R, Harris AL (2004) Macrophage infiltration and angiogenesis in human malignancy. Novartis Found Symp 256:189-200
19. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP (2005) Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 65:3437-3446
20. Buhtoiarov IN, Lum H, Berke G, Sondel PM, Rakhmilevich AL (2006) Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol 176:309-318
21. Wu Q, Buhtoiarov IN, Sondel PM, Rakhmilevich AL, Ranheim EA (2009) Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia. J Immunol 182:6771-6778
22. Johnson EE, Buhtoiarov IN, Baldeshwiler MJ, Felder MAR, Van Rooijen N, Sondel PM, Rakhmilevich AL (2011) Enhanced T cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice. J Immunother 34:76-84
23. Van Rooijen N, Sanders A (1994) Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174:83-93
24. Buhtoiarov IN, Lum H, Berke G, Paulnock D, Sondel PM, Rakhmilevich AL (2005) CD40 ligation induces antitumor reactivity of murine macrophages via an IFN gamma-dependent mechanism. J Immunol 174:6013-6022
25. Elkord E, Alcantar-Orozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE (2010) T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther 10:1573-1586
26. Hegardt P, Widegren B, Sjogren HO (2000) Nitric-oxide-dependent systemic immunosuppression in animals with progressively growing malignant gliomas. Cell Immunol 200:116-127
27. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181:5791-5802
28. Jia W, Jackson-Cook C, Graf MR (2010) Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma ? vaccination model. J Neuroimmunol 223:20-30
29. Ortega A, Carretero J, Obrador E, Estrela JM (2008) Tumoricidal activity of endothelium-derived NO and the survival of metastatic cells with high GSH and Bcl-2 levels. Nitric Oxide 19:107-114
30. Vicetti Miguel RD, Cherpes TL, Watson LJ, McKenna KC (2010) CTL induction of tumoricidal nitric oxide production by intratumoral macrophages is critical for tumor elimination. J Immunol 185:6706-6718
31. Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL (2006) Tumoristatic effects of anti-CD40 mAb-Activated macrophages involve nitric oxide and tumor-necrosis factor-A. Immunology 118:261-270
32. Buhtoiarov IN, Sondel PM, Wigginton JM, Buhtoiarova TN, Yanke EM, Mahvi DA, Rakhmilevich AL (2011) Antitumor synergy of cytotoxic chemotherapy and anti-CD40 plus CpGODN immunotherapy through repolarization of tumor associated macrophages. Immunology 132:226-239
33. Dinapoli MR, Calderon CL, Lopez DM (1996) The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J Exp Med 183:1323-1329
34. Naama HA, McCarter MD, Mack VE, Evoy DA, Hill AD, Shou J, Daly JM (2001) Suppression of macrophage nitric oxide production by melanoma: mediation by a melanoma-derived product. Melanoma Res 11:229-238
35. Atochina O, Daly-Engel T, Piskorska D, McGuire E, Harn DA (2001) A schistosome-expressed immunomodulatory glycoconjugate expands peritoneal Gr1(?) macrophages that suppress naive CD4(?) T cell proliferation via an IFN-gamma and nitric oxide-dependent mechanism. J Immunol 167:4293-4302
36. Dunay IR, Damatta RA, Fux B, Presti R, Greco S, Colonna M, Sibley LD (2008) Gr1(?) inflammatory monocytes are required for mucosal resistance to the pathogen Toxoplasma gondii. Immunity 29:306-317
37. Caso R, Silvera R, Carrio R, Iragavarapu-Charyulu V, Gonzalez- Perez RR, Torroella-Kouri M (2010) Blood monocytes from mammary tumor-bearing mice: early targets of tumor-induced immune suppression? Int J Oncol 37:891-900
38. Greifenberg V, Ribechini E, Rossner S, Lutz MB (2009) Myeloid- derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol 39:2865-2876
39. Pelaez B, Campillo JA, Lopez-Asenjo JA, Subiza JL (2001) Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J Immunol 166:6608-6615
40. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331:1612-1616
41. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, Grassi F, Bronte V (2010) Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 40:22-35
42. Sunderkotter C, Nikolic T, Dillon MJ, van Rooijen N, Stehling M, Drevets DA, Leenen PJM (2004) Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 172:4410-4417
43. Cui SJ, Reichner JS, Mateo RB, Albina JE (1994) Activated murine macrophages induce apoptosis in tumor-cells through nitric-oxide-dependent or nitric-oxide-independent mechanisms. Cancer Res 54:2462-2467
44. Klostergaard J, Leroux ME, Hung MC (1991) Cellular-models of macrophage tumoricidal effector mechanisms in vitro: characterization of cytolytic responses to tumor-necrosis-factor and nitric-oxide pathways in vitro. J Immunol 147:2802-2808
45. Decker T, Lohmannmatthes ML, Gifford GE (1987) Cell-Associated tumor-necrosis-factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 138:957-962
46. Ellyard JI, Quah BJ, Simson L, Parish CR (2010) Alternatively activated macrophage possess antitumor cytotoxicity that is induced by IL-4 and mediated by arginase-1. J Immunother 33:443-452
47. Egilmez NK, Harden JL, Virtuoso LP, Schwendener RA, Kilinc MO (2011) Nitric oxide short-circuits interleukin-12-mediated tumor regression. Cancer Immunol Immunother 60:839-845
48. Fukumura D, Kashiwagi S, Jain RK (2006) The role of nitric oxide in tumour progression. Nat Rev Cancer 6:521-534 (Review
49. Wang GY, Ji B, Wang X, Gu JH (2005) Anti-cancer effect of iNOS inhibitor and its correlation with angiogenesis in gastric cancer. World J Gastroenterol 1:3830-3833
50. Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW (2010) Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 16:1834- 1844
51. Liao S, Cheng G, Conner DA, Huang Y, Kucherlapati RS, Munn LL, Ruddle NH, Jain RK, Fukumura D, Padera TP (2011) Impaired lymphatic contraction associated with immunosuppression. Proc Natl Acad Sci USA 108:18784-18789
52. Tsung K, Dolan JP, Tsung YL, Norton JA (2002) Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 62:5069-5075
53. Weiss JM, Ridnour LA, Back T, Hussain SP, He P, Maciag AE, Keefer LK, Murphy WJ, Harris CC, Wink DA, Wiltrout RH (2010) Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J Exp Med 207:2455-2467
54. Zoglmeier C, Bauer H, Noerenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C (2011) CpG blocks immune suppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res 17:1765-1775
55. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, Bronte V, Zanovello P (2009) IL4Ralpha? myeloid-derived suppressor cell expansion in cancer patients. J Immunol 182:6562-6568